Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Iterum Therapeutics plc
ITRM | US
1.12
USD-0.05
-4.27%
ITRM | US
About Iterum Therapeutics plc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.12
Open
1.20
High
1.25
Low
1.09
Iterum Therapeutics plc a clinical-stage pharmaceutical company engages in developing and commercializing anti-infectives in Ireland Bermuda and the United States. It is developing sulopenem a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections complicated urinary tract infections and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin Ireland.
View LessITRM | US
Risk
63.1
Sharpe
0.50
Luna's Score
34/100
Recommendation
Sell
Luna says (ITRM | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
72.8%1 month
63.1%3 months
69.5%6 months
75.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
6.03
Debt to equity
-1.98
Debt to assets
1.53
Ent. to EBITDA
0.55
Ent. to rev.
105.22
PEG
-
Other Fundamentals
EBITDA
-37.36M
MarketCap
25.43M
MarketCap(USD)
25.43M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-555.68
Short ratio
0.63
Short perc.
0.98
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.44
Range1M
0.44
Range3M
0.60
Volumes: Market Activity
Rel. volume
2.79
Price X volume
687.76K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.55 | - | Par |
| Ent. to Revenue | 105.22 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 6.03 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 69.49 | - | Par |
| Debt to Equity | -1.98 | -1.23 | Cheaper |
| Debt to Assets | 1.53 | 0.25 | Expensive |
| Market Cap | 25.43M | - | Emerging |
